NBIX — NEUROCRINE BIOSCIENCES INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 914475 ·
Last close
$175.77
Market Cap
$17.67B
52W High
$181.18
52W Low
$126.49
ADV30
1,159,326
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 814,500,000 | 800,700,000 | 186,000,000 | 197,900,000 | 4,906,200,000 | 266,500,000 | 1,498,800,000 |
| Dec 2025 | 805,500,000 | 787,900,000 | 227,900,000 | 153,700,000 | 4,631,500,000 | 713,000,000 | 1,378,400,000 |
| Sep 2025 | 794,900,000 | 780,900,000 | 239,300,000 | 209,500,000 | 4,265,700,000 | 340,200,000 | 1,262,100,000 |
| Jun 2025 | 687,500,000 | 676,200,000 | 145,600,000 | 107,500,000 | 3,889,800,000 | 264,000,000 | 1,195,500,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$863,700,000
Investing CF
$-784,800,000
Financing CF
$-6,500,000
CapEx
$-45,500,000
Dividends Paid
—
Buybacks
$-71,700,000
EPS Diluted TTM
$6.49
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$589,600,000
Inventory
$64,500,000
Receivables
$768,100,000
ST Investments
$1,049,700,000
EBIT TTM
$798,800,000
Pretax Income TTM
$937,500,000
Interest Exp TTM
—
Analysts
27
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,102,400,000
EBITDA
$828,600,000
Free Cash Flow
$590,550,016
Enterprise Value
$16,658,079,744
Total Cash
$1,316,199,936
Total Debt
$463,500,000
Shares Out
100,549,983
Trailing EPS
$6.49
Book Value
$33.87
ROE
22.5%
ROA
11.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,860,500,000 | 636,500,000 | 478,600,000 | 4,631,500,000 | 1,378,400,000 | — | 782,700,000 |
| Dec 2024 | 2,355,300,000 | 583,000,000 | 341,300,000 | 3,718,700,000 | 1,129,000,000 | — | 595,400,000 |
| Dec 2023 | 1,887,100,000 | 394,800,000 | 249,700,000 | 3,251,400,000 | 1,019,400,000 | — | 389,900,000 |
| Dec 2022 | 1,488,700,000 | 249,000,000 | 154,500,000 | 2,368,700,000 | 660,900,000 | — | 339,400,000 |
TTM Snapshot
Revenues TTM
$1,804,800,000
NetIncome TTM
$303,900,000
OpCashFlow TTM
$0
Assets (Latest)
$3,718,700,000
Forward EPS
$12.66
Max Pain — expiry 2026-12-18
max pain strike: $160.00 · spot: $175.77 · call oi: 688 · put oi: 3,032Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRNA | Moderna, Inc. | $21.45B | $54.07 | — |
| EXEL | EXELIXIS, INC. | $13.92B | $55.37 | — |
| BNTX | BioNTech SE | $22.59B | $89.33 | — |
| TECH | BIO-TECHNE Corp | $11.16B | $71.60 | — |
| BIIB | BIOGEN INC. | $29.85B | $202.19 | — |
News headlines (Yahoo Finance, 1h cache)
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
2026-07-23 20:05 · Yahoo
Neurocrine Biosciences (NBIX) Stock Trades Fair On Earnings But Mixed On Value
2026-07-23 19:11 · Yahoo
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
2026-07-23 14:00 · Yahoo
Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer
2026-07-22 17:11 · Yahoo
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
2026-07-22 16:22 · Yahoo
Here's Why You Should Add Savara Stock to Your Portfolio Now
2026-07-22 13:21 · Yahoo
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
2026-07-21 20:05 · Yahoo
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
2026-07-21 14:47 · Yahoo
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
2026-07-21 14:20 · Yahoo
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
2026-07-20 13:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.